A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
Terminated · Phase 2, Phase 3 · NCT05269355
Conditions: Leiomyosarcoma
At a glance
- Research payments reported, 2025
- $1.0M
- U.S. investigators named
- 15
- Sites paid
- 16
- Planned or actual enrollment
- 359
About the trial
- Sponsor
- PTC Therapeutics
- Tested
- Unesbulin (drug), Dacarbazine (drug), Placebo (other)
- Dates
- Started 2022-05-23; completion 2024-07-17
- Results posted
- Yes
This study will compare the efficacy and safety of unesbulin plus dacarbazine versus placebo plus dacarbazine in participants with unresectable or metastatic, relapsed or refractory LMS who have received at least 1 prior line of systemic therapy.
From ClinicalTrials.gov, last updated 2025-06-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ptc Therapeutics, Inc. reported $1.0M in research payments for this study in 2025 (36 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Bartosz Chmielowski, MD, PHD Hematology & Oncology · Los Angeles, CA
- Kristen N. Ganjoo, MD Medical Oncology · Stanford, CA
- Janet M. Yoon, M.D. Pediatric Hematology & Oncology · Duarte, CA
- Anthony Elias, MD Medical Oncology · Aurora, CO
- Hari A. Deshpande, MD Interventional Cardiology · New Haven, CT
- Steven Attia, DO Hematology & Oncology · Jacksonville, FL
- Seth M. Pollack, MD Hematology & Oncology · Chicago, IL
- Christian F. Meyer, M.D., PH. D. Medical Oncology · Baltimore, MD
- Juneko E. Grilley-olson, M.D. Hematology & Oncology · Durham, NC
- Sujana Movva, MD Medical Oncology · New York, NY
- Prabhjot S. Mundi, M.D. Medical Oncology · New York, NY
- Christopher W. Ryan, MD Medical Oncology · Portland, OR
- Atrayee Basu Mallick, M.D Hematology & Oncology · Philadelphia, PA
- Lee P. Hartner, MD Hematology & Oncology · Philadelphia, PA
- Shreyaskumar R. Patel Medical Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- City of Hope National Medical Ctr $262,583
- Ronald Reagan UCLA Medical Center, CA $173,922
- Ohsu Hospital and Clinics, OR $169,015
- The Board of Trustees of the Leland Stanford Junior University $102,719
- Ut MD Anderson Cancer Center $66,604
- Northwestern University $62,816
- The Trustees of Columbia University in The City of New York $42,860
- Duke University $30,397
- Memorial Sloan Kettering Cancer Center $27,870
- Mayo Clinic Jacksonville $18,725
- Yale University $13,651
- Regents of the University of Colorado $12,810
- Hospital of Univ of Pennsylvania, PA $8,917
- Washington University Medical School $8,200
- Johns Hopkins University $6,809
- Thomas Jefferson University $3,755
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.